Complete responses (CR) in patients receiving atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).

被引：0

作者：

Finn, Richard S.

Qin, Shukui

Ikeda, Masafumi

Galle, Peter R.

Ducreux, Michel

Kim, Tae-You

Kudo, Masatoshi

Lim, Ho Yeong

Breder, Valeriy Vladimirovich

Merle, Philippe

Kaseb, Ahmed Omar

Li, Daneng

Feng, Yin-Hsun

Verret, Wendy

Xu, Derek-Zhen

Hernandez, Sairy

Ding, Beiying

Zhu, Andrew X.

Cheng, Ann-Lii

机构：

[1] UCLA, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA

[2] Jinling Hosp, Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Med Ctr, Mainz, Germany

[5] Gustave Roussy Canc Campus Grand Paris, Villejuif, France

[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea

[9] NN Blokhin Minist Hlth, Russian Oncol Res Ctr, Moscow, Russia

[10] Hosp La Croix Rousse, Lyon, France

[11] Univ Texas MD Anderson Canc Ctr, GI Med Oncol Dept, Houston, TX 77030 USA

[12] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA

[13] Beckman Res Inst, Duarte, CA USA

[14] Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol, Tainan, Taiwan

[15] Genentech Inc, San Francisco, CA 94080 USA

[16] Roche Prod Dev, Shanghai, Peoples R China

[17] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[18] Natl Taiwan Univ Hosp, Taipei, Taiwan

[19] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4596

引用

页数：2